KRAS Mutation Detection Codon 61 Tissue
MRP - ₹ 6,930
What is a KRAS Mutation Detection Codon 61 Tissue?
The KRAS Mutation Detection Codon 61 Tissue Test is a molecular diagnostic test that analyzes tumor tissue to identify mutations in the KRAS gene, specifically at codon 61. KRAS mutations are commonly associated with certain cancers, including colorectal, lung, and pancreatic cancers, and can influence how a patient responds to targeted therapies. Doctors recommend this test to guide personalized treatment decisions, predict drug resistance, and improve outcomes by tailoring therapy based on the genetic profile of the tumor.
Additional Information
| Also known as/ Other names: | KRAS Codon 61 Mutation Analysis, KRAS Gene Mutation Test (Codon 61), KRAS Codon 61 Molecular Testing, KRAS Tissue Mutation Panel |
| Parameters: | 1 |
| Recommended for: | M/F/Others |
| Sample Type: | FFPE Tissue block |
| Patient Preparation: | No prior preparation is needed |
| Reports: | 7 days |
FAQs
It identifies mutations in the KRAS gene at codon 61, which are linked to cancer growth and treatment resistance.
KRAS mutations influence how tumors respond to targeted therapies. Detecting them helps doctors personalize treatment strategies for better outcomes.
Patients diagnosed with colorectal, lung, or pancreatic cancers are often recommended for KRAS mutation testing to guide therapy decisions.
A positive result indicates the presence of a KRAS codon 61 mutation, which may affect treatment response.
A negative result means no KRAS codon 61 mutation was detected, suggesting better response to certain targeted therapies.
PCR-based testing is highly accurate and sensitive in detecting specific KRAS mutations in tumor tissue.